The PennZone

  • Home
  • Business
  • Technology
  • Non-profit
  • Construction
  • Health
  • Real Estate
  • Travel
  • Legal

Children's Hospital of Philadelphia Researchers Develop Cell Atlas to Uncover Significant Shifts in the Neuroblastoma Tumor Microenvironment
The PennZone/10301237

Trending...
  • Platinum Car Audio LLC Focuses on Customer-Driven Vehicle Audio and Electronics Solutions
  • OpenSSL Corporation Advisory Committees' Elections 2026: Results Announcement
  • Mecpow M1: A Safe & Affordable Laser Engraver Built for Home DIY Beginners
PHILADELPHIA, April 14, 2025 ~ A team of researchers at Children's Hospital of Philadelphia (CHOP) has made a significant breakthrough in the understanding of neuroblastoma, a common and potentially deadly childhood cancer. Led by senior study author Kai Tan, PhD, the team developed a longitudinal atlas of neuroblastoma to gain deeper insights into the molecular mechanisms underlying treatment resistance.

Published in the journal Nature Genetics, the study offers valuable new insights that could potentially lead to personalized medicine approaches in neuroblastoma treatment. Despite significant advances in standard care, the 5-year survival rate for high-risk neuroblastoma remains less than 50%. One of the major challenges in treating this cancer is its heterogeneity, with different cells within the same tumor exhibiting varying characteristics.

The lack of understanding about how these cells interact and change during treatment has been a major barrier in developing effective therapies. In this study, researchers created a cell atlas that provided an in-depth look at how different cell types, such as malignant cells and immune cells, interact and change within their natural environment.

More on The PennZone
  • Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships
  • Primeindexer Google indexing platform launched by SEO Danmark APS
  • Kaltra Introduces New Downward-Spraying Distribution Technology to Boost Microchannel Evaporator Performance
  • Talentica Announces Winners of Multi-Agent Hackathon 2026
  • Special Alert: Undervalued Opportunity: IQSTEL (N A S D A Q: IQST) Positioned for Explosive Multi-Year Growth

"Our atlas provides a crucial foundation for developing novel treatments by mapping the complex interactions between malignant cells and surrounding cells that support tumor growth," said Dr. Tan. "As researchers, we look to use these insights to tailor therapies to target unique characteristics of a patient's tumor. Overall, we are optimistic about the doors our research and techniques are opening."

To create this atlas, CHOP researchers used advanced single-cell sequencing and spatial omics techniques to analyze tumor samples from 22 pediatric patients with high-risk neuroblastoma before and after chemotherapy. This multidimensional dataset is now available on the National Cancer Institute (NCI) Human Tumor Atlas Network (HTAN) data portal.

The team uncovered diverse characteristics of both tumor and non-tumor cells, as well as major changes in these characteristics following chemotherapy. They found that patients had worse outcomes when cancer cells were multiplying more actively and became more metabolically active. On the other hand, tumors that developed more mature, neuron-like features resulted in better outcomes for patients.

Additionally, the researchers found that an increase in a type of mesenchymal-like tumor cells was linked to poorer responses to chemotherapy. They also discovered that certain immune cells, such as macrophages, became more active in ways that promoted tumor growth by enabling blood vessel growth while suppressing the immune response.

More on The PennZone
  • Triple-Digit Growth, Strategic N A S D A Q Uplist, Plus A Scalable Healthcare Rollout Model: Stock Symbol: CDIX
  • Vesica Health Receives FDA Breakthrough Device Designation for AssureMDx
  • Lineus Medical's SafeBreak® Vascular Added to Alliant GPO Contract
  • Cancun All Inclusive is ready for Spring Break 2026 with new Resorts, Exclusive Deals, activities and more!
  • 66% of US Bankruptcies Are Medical — So Americans Are Building Businesses That Cover Healthcare Emergencies

One of the most significant findings of the study was a specific communication pathway between macrophages and cancer cells (HB-EGF/ERBB4) that triggered signals promoting tumor growth. This highlights the importance of identifying new factors within the tumor microenvironment that influence treatment response. The team is now conducting further studies using preclinical models to test this pathway and potentially develop novel therapeutic strategies.

"This study would not have been possible without the monumental team efforts of biologists, clinicians, and computational scientists," said lead author Wenbao Yu, PhD. "With their collaboration, we were able to gain new insights into the complex ecosystem of neuroblastoma."

The research was supported by a grant from the National Cancer Institute (NCI) Human Tumor Atlas Network (#U2C CA233285), as well as grants from the National Institutes of Health (NIH) (U54 HL165442), American Cancer Society Institutional Research Grant (IRG-22-150-41-IRG), and NIH (T32 CA009140).

This groundbreaking study, titled "Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring," was published online on April 14th, 2025 in Nature Genetics. The DOI for this article is 10.1038/s41588-025-02158-6.
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Josh Stout "The Western Project"
  • Open House Momentum Builds at Heritage at South Brunswick
  • A Celebration of Visibility, Voice and Excellence: The 57th NAACP Image Awards Golf Invitational, Presented by Wells Fargo, A PGD Global Production
  • TopDogTours Expands Award-Winning Walking Tours in Philadelphia with Immersive Experiences
  • Athens in Spring: A Culinary City Break That Rivals Paris and Copenhagen
  • ClearSight Therapeutics Signs LOI with Covalent Medical for $60M Multi-Channel OTC Eye Care Partnership
  • Jayne Williams Joins Century Fasteners Corp. Sales and Business Development Team
  • Lord of the Rings Star Orlando Bloom To Host Special Experience at FAN EXPO Philadelphia
  • Rocket Fibre Services Growing Customer Base With netElastic Networking Software
  • Cummings Graduate Institute for Behavioral Health Studies Honors New Doctor of Behavioral Health Graduates
  • IDpack v4 Launches: A Major Evolution in Cloud-Based ID Card Issuance
  • Corey Lakins Set to Launch Glow Your Influence, a Podcast Spotlighting Women Leaders
  • CCHR Says Psychiatry's Admission on Antidepressant Withdrawal Comes Far Too Late
  • 505 Plumbing, Heating & Cooling Launches in Albuquerque, Bringing a Customer-First Approach to Home Services
  • As AI.com Sells For Record $70 Million, Attention Now Turns To ArtificialIntelligence.com
  • AOW Event Sponsored By The Stanglwirt Resort a renowned five-star Austrian wellness destination
  • Average US gambler spends $210 per month in 2026
  • 10X Recruitment Launches Operator-Led Executive Search for Behavioral Health and Legal Leaders
  • Integris Composites developing armor for military in Arctic Circle
  • Caraline Skincare's Gentle Glow Cleansing Oil Named Finalist for Best Face Cleanser at the 2026 CertClean Clean Beauty Awards​

Popular on PennZone

  • Still Using Ice? FrostSkin Reinvents Hydration
  • OneVizion Announces Next Phase of Growth as Brad Kitchens Joins Board of Directors
  • Cold. Clean. Anywhere. Meet FrostSkin
  • Ice Melts. Infrastructure Fails. What Happens to Clean Water?
  • Luxury Lake-View Home Launches in Kissimmee's Bellalago community, Offering Privacy, Space, and Florida Resort-Style Living
  • Roshni Online Services Unveils Plans for Innovative Digital Consultation Platform
  • Wala Blegay to Announce Run for Congress in Maryland's 5th District on Feb. 4
  • Jacob Emrani's Annual "Supper Bowl" Expected To Donate Thousands Of Meals
  • Star-powered Kappa Takeover Weekend Returns to the DMV June 18- 21, 2026, Hosted By Comedian Joe Clair W/ Dj Quick Silva (the Party Kingpin)
  • Market Value Enhancement From 2 Important New US Patents Issued for Strengthening Hair Enzyme Booster Technology to Caring Brands (NAS DAQ: CABR)

Similar on PennZone

  • VENUS Goes Live on CATEX Exchange As UK Financial Ltd Activates The Premier Division Of The Maya Meme's League
  • Atlanta Tech Founder Seeks Clarity on Intellectual Property and Innovation Policy
  • Special Alert: Undervalued Opportunity: IQSTEL (N A S D A Q: IQST) Positioned for Explosive Multi-Year Growth
  • Triple-Digit Growth, Strategic N A S D A Q Uplist, Plus A Scalable Healthcare Rollout Model: Stock Symbol: CDIX
  • 66% of US Bankruptcies Are Medical — So Americans Are Building Businesses That Cover Healthcare Emergencies
  • Ludex Partners With Certified Trading Card Association (CTCA) To Elevate Standards And Innovation In The Trading Card Industry
  • ASTI Ignites the Space Economy: Powering SpaceX's NOVI AI Pathfinder with Breakthrough Solar Technology: Ascent Solar Technologies (N A S D A Q: ASTI)
  • Hiring has reached a "Digital Stalemate"—Now, an ex-Google recruiter is giving candidates the answers
  • Platinum Car Audio LLC Focuses on Customer-Driven Vehicle Audio and Electronics Solutions
  • Postmortem Pathology Expands Independent Autopsy Services in Kansas City
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us